



## ASX Announcement

17 February 2025

### Wellnex Life Limited Entitlement Offer to raise up to \$22.1 million opens today

#### Announcement Highlights

- Wellnex Life (**Wellnex** or **the Company**) announces plans to raise up to \$22.1 million via a 1:1 non-renounceable entitlement offer at \$0.65 per share (**the Offer** or **Entitlement Offer**), representing a discount of 8.6% to 30-VWAP (pre-announcement).
- Wellnex has received initial conditional binding commitments of A\$9 million to cornerstone its capital raise, on the same terms of the Offer, for the proposed dual listing on the AIM Market of the London Stock Exchange plc (**AIM**). These commitments are conditional upon, inter alia, completion of the AIM listing.
- The Offer is made in conjunction with the Company's intended dual listing on AIM which is being marketed to UK and Australian investors in parallel and on the same terms.
- Marketing continues and the Company looks forward to building on the initial demand.
- Funds raised will serve to redeem Wellnex's convertible notes, pay the outstanding deferred consideration for Pain Away and fund general working capital purposes, including the costs of the Offer and the AIM listing.
- **Request an electronic copy of your personal application form here**  
<https://wellnexlife.investorportal.com.au/request-form/>

**Wellnex Life Limited Ltd (ASX: WNX)** is pleased to announce its non-renounceable Entitlement Offer, at 0.65 per share, to raise up to \$22.1 million opens today. The Offer is not underwritten.

Wellnex has commenced a marketing campaign for the proposed dual listing on AIM, with strong interest received from UK institutions and sophisticated investors. The Company has decided to proceed with the Entitlement Offer to ensure all Eligible Shareholders (as defined below) have the first right to participate in the Offer.

The Entitlement Offer Booklet and personalised Entitlement and Acceptance Form for the Offer, as announced on 10 February 2025, have been dispatched to eligible shareholders today.

Funds raised under the Entitlement Offer will be used to redeem the convertible notes, pay the outstanding deferred consideration for Pain Away and fund general working capital, including the costs of the Entitlement Offer and the proposed AIM listing. The extinguishment of the Company's convertible notes and settlement of the Pain Away deferred consideration will result in the Company saving circa \$1.4 million in annual costs.



## Entitlement Offer

As announced to the ASX on 10 February 2025, the Company is inviting shareholders to participate in the non-renounceable pro-rata Entitlement Offer of one (1) New Share for every one (1) Share held at the Record Date of 13 February 2025, at an Issue Price of \$0.65 per New Share (Offer).

**Shareholders can request an electronic copy of their personalised Entitlement Offer application form at - <https://wellnexlife.investorportal.com.au/request-form/>**

The closing date for the Offer is Wednesday 26 February 2025, at 5pm (AEDT).

Reach Markets are the advisers managing the Offer and can be contacted on 1300 805 795 or via [advisers@reachmarkets.com.au](mailto:advisers@reachmarkets.com.au)

Shareholders (other than Directors and related parties of the Company) may subscribe for **Additional Shares** beyond their entitlement of 1 for 1 on the basis that some existing shareholders may be either ineligible (non-Australian or New Zealand residents) or may fail to fully take up their Entitlement. This additional ability is restricted only to eligible holders and is referred to as a **Top-Up Facility**.

If there remains any Shortfall after allocation of the Additional Shares, the Directors reserve the right for up to 3 months after the close of the Offer to place any Shortfall to wholesale or exempt investors at the Board's discretion but at a price no less than the Offer Price (**Shortfall Placement**).

## Join a briefing

Join Managing Director of Wellnex Zack Bozinovski for a live and interactive shareholder briefing where he will discuss the Entitlement Offer, use of funds and how to participate.

Click here to register for a session: <https://wellnexlife.investorportal.com.au/live-shareholder-briefing/>

## Company update

Wellnex is a growing and diverse consumer healthcare business that has spent the past years building a strong portfolio of own brands and licensing deals including own developed brands Wakey Wakey and Nighty Night, leading topical pain relief brand Pain Away (acquired in 2023) and IP licensing agreements with domestic and global pharmaceutical companies, including Haleon.

These efforts are now bearing fruit, with revenues growing over 112% in H1 FY25 versus the prior comparative period including revenue from Wellnex's brands up 182% and IP licensing up 64% for the same period. Wellnex under the global extension of the Haleon arrangement has delivered its first product for the UK market.

	July – Dec 2023	July – Dec 2024	% Change
Brands	\$3.0 million	\$8.47 million	182%
IP Licensing	\$2.12 million	\$3.47 million	64%
Brokerage	\$0.51 million	\$0	N/A
Total	\$5.63 million	\$11.94 million	112%



Wellnex's global ambitions, particularly the successful collaboration with Haleon – one of the largest consumer health companies in the world and listed on the London Stock Exchange – sparked the Company's proposal of a dual listing on AIM, which is part of one of the world's most respected public exchanges, the London Stock Exchange.

This announcement was authorised for release to the market by the board of Wellnex Life Limited.

**For further information, please contact:**

George Karafotias

Reach Markets (Lead Manager)

T: +61 3 8399 9419

T: 1300 805 795

E: [george.k@wellnexlife.com.au](mailto:george.k@wellnexlife.com.au)

E: [IR@reachmarkets.com.au](mailto:IR@reachmarkets.com.au)

For shortfall enquiries

[Patrick.Nelson@reachcorporate.com.au](mailto:Patrick.Nelson@reachcorporate.com.au)

[Michael@barclaypearce.com.au](mailto:Michael@barclaypearce.com.au)

To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: <https://wellnexlife.investorportal.com.au/register/>

**IMPORTANT INFORMATION**

This announcement is issued by Wellnex Life. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Wellnex in any jurisdiction. This announcement does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of entitlements or fully paid ordinary shares in Wellnex Life. Nothing contained in this document constitutes investment, legal, tax or other advice. The information in this announcement is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. If you are unsure of your position, please contact your accountant, tax advisor, stockbroker or other professional advisor.

**NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. No action has been or will be taken to register, qualify or otherwise permit a public offering of the New Shares under the Entitlement Offer in any jurisdiction outside Australia and New Zealand. In particular, the New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Wellnex Life Limited  
Building 2, Level 3, Suite 69, 574 Plummer Street  
Port Melbourne VIC Australia  
[info@wellnexlife.com.au](mailto:info@wellnexlife.com.au) Phone: +61 3 8399 9419